US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Astellas Pharma, Inc.

15.07

-0.3625-2.35%

Volume:35.32K

Turnover:533.62K

Market Cap:26.98B

PE:202.65

High:15.31

Open:15.00

Low:14.93

Close:15.43

52wk High:17.35

52wk Low:8.97

Shares:1.79B

Float Shares:1.75B

Volume Ratio:0.88

T/O Rate:0.00%

Dividend:0.51

Dividend Rate:3.40%

EPS(TTM):0.0744

EPS(LYR):0.0628

ROE:19.82%

ROA:7.38%

PB:2.44

PE(LYR):239.77

Loading ...

Overview Company News Filings

Earning Preview: Astellas Pharma, Inc. this quarter’s revenue is expected to increase, and institutional views are mixed with a cautious tilt

Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer

Astellas, Pfizer announce FDA grants priority review to PADCEV, Keytruda sBLA

Astellas Pharma: Under Prescription Drug User Fee Act (Pdufa), FDA Has Set Target Action Date of August 17, 2026

THOMSON REUTERS

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

BRIEF-Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer

Pfizer, Astellas announce results from Phase 3 EV-304 trial for PADCEV

Astellas- Safety Profile for Perioperative Enfortumab Vedotin Plus Pembrolizumab Observed in EV-304 Consistent With Prior Experience With Combination

THOMSON REUTERS

Astellas, Vir announce global strategic collaboration

Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study

FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":15.0675,"timestamp":1777302420000,"preClose":15.43,"halted":0,"volume":35322,"delay":15,"changeRate":-0.023493195074530068,"floatShares":1745183156,"shares":1790310070,"eps":0.074352,"marketStatus":"Trading","change":-0.3625,"latestTime":"04-27 11:07:00 EDT Delay","open":15,"high":15.31,"low":14.9316,"amount":533618.884974,"amplitude":0.024524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777320000000},"marketStatusCode":2,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":15.43,"volumeRatio":0.875889},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1745183156,"roa":"7.38%","roe":"19.82%","lyrEps":0.062841,"volumeRatio":0.875889,"shares":1790310070,"dividePrice":0.5124,"high":15.31,"amplitude":0.024524,"preClose":15.43,"low":14.9316,"week52Low":8.97,"pbRate":"2.44","psRate":"2.08","week52High":17.35,"institutionHeld":0,"latestPrice":15.0675,"eps":0.074352,"divideRate":0.034007,"volume":35322,"delay":15,"ttmEps":0.074352,"open":15,"prevYearClose":13.29,"prevWeekClose":15.43,"prevMonthClose":16.22,"prevQuarterClose":16.22,"fiveDayClose":16.18,"twentyDayClose":16.09,"sixtyDayClose":13.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"date":"2026-04-27","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1777276800000,"name":null,"time":"","dateTimestamp":1777262400000,"actualEps":null},{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1758254400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170654788","title":"Earning Preview: Astellas Pharma, Inc. this quarter’s revenue is expected to increase, and institutional views are mixed with a cautious tilt","url":"https://stock-news.laohu8.com/highlight/detail?id=1170654788","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170654788?lang=en_us&edition=fundamental","pubTime":"2026-04-20 10:33","pubTimestamp":1776652404,"startTime":"0","endTime":"0","summary":"Abstract Astellas Pharma, Inc. will report on April 27, 2026 after market close; this preview summarizes last quarter’s performance, current-quarter revenue and earnings projections, segment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Astellas Pharma, Inc. this quarter’s revenue is expected to increase, and institutional views are mixed with a cautious tilt","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALPMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628476037","title":"Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2628476037","media":"Dow Jones","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628476037?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:29","pubTimestamp":1776684540,"startTime":"0","endTime":"0","summary":"Merck, Pfizer and Astellas Pharma have won U.S. Food and Drug Administration priority review for their applications seeking expanded approval of their Keytruda/Padcev drug combination in certain patients with a hard-to-treat form of bladder cancer.The companies on Monday said the applications cover Merck's Keytruda and Keytruda QLEX, each coupled with Padcev from Pfizer and Astellas, for the treatment of patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. The companies said the FDA has set a target action date of Aug. 17 for the applications.The FDA previously approved the combination of Keytruda and Padcev for adults with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.Merck in 2019 signed a deal to evaluate the combinat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1917777945.USD","LU1066051225.USD","LU2461242641.AUD","LU2361045086.USD","IE0002270589.USD","LU2357627491.SGD","SG9999014575.USD","LU2468319806.SGD","SG9999015341.SGD","LU1941712348.USD","LU1929549753.HKD","BK4559","SG9999001176.SGD","LU1699723380.USD","SG9999002232.USD","LU1430594728.SGD","LU1941712264.USD","BK4516","LU1934455277.USD","LU0289739699.SGD","LU1023059063.AUD","LU0985481810.HKD","LU1066051811.HKD","LU2106854487.HKD","LU0234572021.USD","LU0006306889.USD","LU1037948541.HKD","LU0942090050.USD","LU0170899867.USD","BK4533","MRK","LU0868494708.USD","LU1066051498.USD","SG9999013999.USD","BK4550","LU0130102774.USD","BK4592","LU2023250843.SGD","LU1116320901.HKD","LU0868494617.USD","LU1585245621.USD","BK4588","LU1934455194.USD","LU2089984988.USD","SG9999014542.SGD","LU0965509283.SGD","IE00BLSP4452.SGD","LU1983299246.USD","IE00B19Z3B42.SGD","LU2360032135.SGD","LU0266013472.USD","LU1974910355.USD","BK4599","LU1201861249.SGD","LU0306807586.USD","PFE","ALPMY","BK4585","LU1989771016.USD","LU0106261372.USD","LU1894683264.USD","LU1894683348.USD","LU0320765646.SGD","LU0130517989.USD","LU0965509101.SGD","IE000M9KFDE8.USD","IE0009355771.USD","LU0208291251.USD","LU0306806265.USD","LU0321505868.SGD","LU0211331839.USD","LU1162221912.USD","LU1883839398.USD","LU0477156953.USD","BK4534","SG9999001176.USD","LU1291159041.SGD","SG9999014567.USD","LU0980610538.SGD","IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","LU1989772840.SGD","IE00BBT3K403.USD","LU0861579265.USD","LU0098860793.USD","LU2324357040.USD","LU0648001328.SGD","LU0225771236.USD","LU1989772923.USD","LU1934455863.HKD","SG9999011175.SGD","SG9999014559.SGD","LU0203345920.USD","LU0859254822.USD","LU1035773651.USD","LU0965509010.AUD","LU1037948897.HKD","LU1057294990.SGD","IE00BLSP4239.USD","LU2125154778.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","LU0203347892.USD","IE00B19Z3581.USD","IE00BN8TJ469.HKD","LU2112291526.USD","IE00B4R5TH58.HKD","LU0965508806.USD","IE0002141913.USD","LU1116320737.USD","LU2125154935.USD","SG9999001440.SGD","LU0122379950.USD","SGXZ57979304.SGD","LU1093756168.USD","LU0070302665.USD","LU0265550946.USD","LU2361044949.HKD","SG9999015358.SGD","IE00BJT1NW94.SGD","LU1069347547.HKD","BK4568","LU1061106388.HKD","LU2023250504.SGD","LU1571399168.USD","LU0265550359.USD","LU0985320562.USD","LU0320765489.SGD","LU2361044865.SGD","SG9999002224.SGD","IE00BSNM7G36.USD","LU0432979614.USD","BK4581","LU0321505439.SGD","LU0456855351.SGD","LU1066053197.SGD","SG9999003800.SGD","LU0238689110.USD","IE00B2B36J28.USD","BK4007","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742003","title":"Astellas, Pfizer announce FDA grants priority review to PADCEV, Keytruda sBLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742003","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742003?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:13","pubTimestamp":1776683611,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) and Pfizer (PFE) announced that the U.S. Food and Drug Administration accepted for Priority Review a supplemental Biologics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announce-fda-grants-priority-review-to-padcev-keytruda-sbla-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announce-fda-grants-priority-review-to-padcev-keytruda-sbla-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","IE00BLSP4239.USD","LU1093756325.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","BK4550","IE0002141913.USD","LU0859254822.USD","LU1069347547.HKD","LU0006306889.USD","LU1585245621.USD","IE000M9KFDE8.USD","LU0265550946.USD","LU0266013472.USD","LU2468319806.SGD","LU1894683264.USD","BK4516","LU2112291526.USD","LU1066051498.USD","IE00BJJMRZ35.SGD","LU0861579265.USD","LU1934455277.USD","SG9999015341.SGD","SG9999002224.SGD","PFE","SG9999013999.USD","BK4592","LU1057294990.SGD","LU0321505868.SGD","IE00BLSP4452.SGD","BK4568","LU2361044865.SGD","LU2089984988.USD","LU0306806265.USD","IE00BFTCPJ56.SGD","LU1929549753.HKD","LU1883839398.USD","LU0130517989.USD","IE00BJT1NW94.SGD","LU1699723380.USD","LU1116320737.USD","BK4585","LU1061106388.HKD","LU0648001328.SGD","SG9999003800.SGD","LU2324357040.USD","BK4581","LU0211331839.USD","LU2125154935.USD","LU0203347892.USD","LU1116320901.HKD","LU1974910355.USD","LU0477156953.USD","SG9999014575.USD","BK4599","SG9999001440.SGD","LU0203345920.USD","LU1430594728.SGD","LU0868494617.USD","LU0942090050.USD","LU2023250504.SGD","SG9999015358.SGD","LU0130102774.USD","LU1066053197.SGD","LU1941712264.USD","LU0320765646.SGD","LU0225771236.USD","LU1066051811.HKD","LU2361044949.HKD","LU2360032135.SGD","LU0170899867.USD","LU1917777945.USD","LU1571399168.USD","BK4007","SG9999011175.SGD","LU0432979614.USD","LU1066051225.USD","LU0965509010.AUD","LU1894683348.USD","IE00B19Z3581.USD","LU0320765489.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU0238689110.USD","LU0208291251.USD","BK4588","IE00B2B36J28.USD","LU0106261372.USD","LU0225284248.USD","LU0980610538.SGD","LU1291159041.SGD","IE00B4R5TH58.HKD","LU0321505439.SGD","SG9999001176.SGD","LU1989772923.USD","IE0009355771.USD","LU1162221912.USD","LU0456855351.SGD","IE0002270589.USD","LU2461242641.AUD","LU2125154778.USD","LU0265550359.USD","IE00BN8TJ469.HKD","IE00B1BXHZ80.USD","LU1023059063.AUD","LU1035773651.USD","LU1989772840.SGD","LU1941712348.USD","LU0868494708.USD","LU1934455194.USD","SG9999002232.USD","SG9999014559.SGD","LU0306807586.USD","SG9999014542.SGD","LU1093756168.USD","LU0965509101.SGD","LU2023250843.SGD","LU0985481810.HKD","LU1037948541.HKD","IE00BBT3K403.USD","LU0965508806.USD","LU0289739699.SGD","BK4533","BK4559","LU1983299246.USD","LU2361045086.USD","LU0985320562.USD","IE00BSNM7G36.USD","SG9999014567.USD","LU2106854487.HKD","LU1201861249.SGD","LU0098860793.USD","LU1037948897.HKD","LU0965509283.SGD","LU1989771016.USD","LU2357627491.SGD","ALPMY","SG9999001176.USD","LU0070302665.USD","LU0234572021.USD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628744145","title":"Astellas Pharma: Under Prescription Drug User Fee Act (Pdufa), FDA Has Set Target Action Date of August 17, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628744145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628744145?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:45","pubTimestamp":1776681901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nTUA3NYLBJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999002224.SGD","LU0122379950.USD","IE000M9KFDE8.USD","SG9999013999.USD","BK4592","BK4588","BK4007","LU0306806265.USD","LU0058720904.USD","LU1894683264.USD","LU0234572021.USD","BK4568","LU0289739699.SGD","BK4585","LU1066053197.SGD","SG9999001176.USD","LU1023059063.AUD","SG9999001176.SGD","SG9999003800.SGD","BK4534","IE00BLSP4452.SGD","LU0306807586.USD","SG9999002232.USD","ALPMY","IE00BBT3K403.USD","LU0321505868.SGD","LU0985481810.HKD","LU1894683348.USD","LU0170899867.USD","IE00B19Z3581.USD","LU1883839398.USD","BK4599","LU0321505439.SGD","LU0225771236.USD","ALPMF","IE00BLSP4239.USD","BK4581","LU0456855351.SGD","LU1057294990.SGD","SGXZ57979304.SGD","LU0868494617.USD","LU0225284248.USD","BK4533","BK4550","SG9999011175.SGD","IE00B19Z3B42.SGD","LU1066051498.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627215706","title":"Vir Biotechnology closes global collaboration agreement with Astellas Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627215706","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627215706?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:17","pubTimestamp":1776345430,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) announced that its global collaboration and licensing agreement with Astellas (ALPMY) announced on February 23 has closed f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-closes-global-collaboration-agreement-with-astellas-pharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-closes-global-collaboration-agreement-with-astellas-pharma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR","BK4535","ALPMY","BK4585","BK4568","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614506258","title":"BRIEF-Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2614506258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614506258?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:32","pubTimestamp":1772206329,"startTime":"0","endTime":"0","summary":"BRIEF-Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder CancerFeb 27 (Reuters) - Astellas Pharma Inc 4503.T:PADCEV + KEYTRUDA CUTS RISK OF RECURRENCE O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN2HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","BK4550","LU1057294990.SGD","ALPMY","IE00BLSP4452.SGD","SG9999002224.SGD","SG9999013999.USD","LU0985481810.HKD","BK4599","BK4568","BK4588","BK4592","BK4534","SG9999001176.USD","LU0868494617.USD","LU0321505868.SGD","LU0225771236.USD","IE0002270589.USD","LU0170899867.USD","LU0289739699.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","LU1023059063.AUD","BK4581","BK4533","SG9999003800.SGD","SG9999011175.SGD","BK4585","IE00BLSP4239.USD","LU0306806265.USD","LU0456855351.SGD","LU1066053197.SGD","SGXZ57979304.SGD","BK4007","LU0234572021.USD","LU1066051498.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","LU0058720904.USD","LU1883839398.USD","LU1894683264.USD","SG9999002232.USD","SG9999001176.SGD","LU0122379950.USD","LU0306807586.USD","LU0225284248.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857067","title":"Pfizer, Astellas announce results from Phase 3 EV-304 trial for PADCEV","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857067","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614857067?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:12","pubTimestamp":1772205142,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) and Astellas Pharma (ALPMY) announced positive results from the Phase 3 EV-304 clinical trial for PADCEV, a Nectin-4 directed antibody...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pfizer-astellas-announce-results-from-phase-3-ev-304-trial-for-padcev-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pfizer-astellas-announce-results-from-phase-3-ev-304-trial-for-padcev-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1066051498.USD","LU0225771236.USD","BK4585","LU0170899867.USD","LU1894683264.USD","IE00BBT3K403.USD","LU1894683348.USD","SG9999003800.SGD","SG9999011175.SGD","LU0321505868.SGD","LU0868494617.USD","SG9999013999.USD","LU1057294990.SGD","BK4581","LU0456855351.SGD","LU0321505439.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","BK4588","BK4568","BK4550","LU0306806265.USD","SG9999002232.USD","IE0002270589.USD","LU0234572021.USD","BK4534","IE00B19Z3B42.SGD","LU0985481810.HKD","SG9999001176.USD","LU0306807586.USD","SG9999002224.SGD","SG9999001176.SGD","LU0289739699.SGD","BK4592","LU0058720904.USD","LU1883839398.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU0225284248.USD","LU0122379950.USD","SGXZ57979304.SGD","BK4599","PFE","ALPMY","BK4007","BK4533","IE00BLSP4452.SGD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857328","title":"Astellas- Safety Profile for Perioperative Enfortumab Vedotin Plus Pembrolizumab Observed in EV-304 Consistent With Prior Experience With Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614857328?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:00","pubTimestamp":1772204408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN2HX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683264.USD","SG9999001176.SGD","BK4599","IE00B19Z3581.USD","BK4585","SG9999013999.USD","SG9999002232.USD","BK4550","LU1066051498.USD","BK4534","LU0321505439.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","ALPMY","LU0456855351.SGD","LU0234572021.USD","LU0306807586.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","IE00BBT3K403.USD","BK4533","LU0058720904.USD","LU0225771236.USD","LU1883839398.USD","LU0170899867.USD","IE00BLSP4239.USD","LU0122379950.USD","LU1057294990.SGD","IE0002270589.USD","LU0985481810.HKD","SG9999011175.SGD","LU0306806265.USD","BK4581","BK4568","LU1066053197.SGD","LU0868494617.USD","SGXZ57979304.SGD","BK4592","LU0225284248.USD","BK4007","SG9999001176.USD","LU0321505868.SGD","LU1894683348.USD","SG9999002224.SGD","BK4588","IE00BLSP4452.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613535757","title":"Astellas, Vir announce global strategic collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2613535757","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613535757?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:05","pubTimestamp":1771884313,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) and Vir Biotechnology (VIR) announced they have entered into a global strategic collaboration to advance VIR-5500, an inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-vir-announce-global-strategic-collaboration-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-vir-announce-global-strategic-collaboration-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMY","BK4139","BK4568","VIR","BK4535","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592971859","title":"Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971859","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592971859?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:38","pubTimestamp":1765975080,"startTime":"0","endTime":"0","summary":"A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer.The companies on Wednesday said Merck's Keytruda coupled with Padcev from Pfizer and Astellas showed significantly improved survival for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.The study met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival, as well as in overall survival, a key secondary endpoint, the companies said.Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, said they plan to discuss the study results with global health authorities for potential regulatory filings.Merck in 2019 inked a deal to evaluate the combination of its block","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","SG9999003800.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU1983299246.USD","LU1974910355.USD","PFE","LU0965509010.AUD","LU1116320737.USD","LU0321505439.SGD","LU1093756325.SGD","SG9999014567.USD","LU2112291526.USD","LU2461242641.AUD","SG9999014542.SGD","LU0203345920.USD","LU2360032135.SGD","LU0289739699.SGD","LU1989772923.USD","LU1941712348.USD","LU0130517989.USD","IE00BLSP4452.SGD","LU0265550946.USD","LU1037948541.HKD","BK4516","LU0211331839.USD","LU0238689110.USD","LU0058720904.USD","LU0306806265.USD","LU0456855351.SGD","LU1941712264.USD","BK4568","LU2125154778.USD","LU0098860793.USD","LU0965509283.SGD","LU2125154935.USD","BK4581","LU1291159041.SGD","BK4592","BK4007","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2361044865.SGD","SGXZ57979304.SGD","LU0985320562.USD","LU1023059063.AUD","ALPMY","LU0648001328.SGD","LU2106854487.HKD","LU1929549753.HKD","BK4599","LU1201861249.SGD","LU1093756168.USD","LU1917777945.USD","LU2361045086.USD","LU1066051225.USD","SG9999015358.SGD","IE00B4R5TH58.HKD","LU0225771236.USD","LU0070302665.USD","LU0965508806.USD","MRK","SG9999001440.SGD","SG9999015341.SGD","SG9999001176.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0225284248.USD","IE00B2B36J28.USD","LU0208291251.USD","LU0980610538.SGD","SG9999001176.SGD","SG9999014559.SGD","SG9999002232.USD","SG9999011175.SGD","LU1894683348.USD","LU1430594728.SGD","IE00BBT3K403.USD","LU2468319806.SGD","LU0130102774.USD","BK4534","LU0266013472.USD","IE00B19Z3B42.SGD","LU0006306889.USD","LU0234572021.USD","LU2324357040.USD","LU2089984988.USD","IE0002270589.USD","LU0106261372.USD","LU0122379950.USD","BK4559","SG9999002224.SGD","LU0265550359.USD","LU0320765489.SGD","LU0203347892.USD","LU1066053197.SGD","LU1066051811.HKD","BK4550","BK4588","LU1162221912.USD","SG9999014575.USD","LU0477156953.USD","LU0861579265.USD","LU2023250504.SGD","IE00B1BXHZ80.USD","LU1894683264.USD","LU1934455277.USD","BK4585","LU0170899867.USD","LU0321505868.SGD","LU1883839398.USD","IE00B19Z3581.USD","LU2361044949.HKD","LU1116320901.HKD","SG9999013999.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1037948897.HKD","LU1989772840.SGD","IE00BSNM7G36.USD","LU0985481810.HKD","LU1585245621.USD","LU2023250843.SGD","LU1066051498.USD","LU1934455194.USD","IE0009355771.USD","LU0306807586.USD","LU1934455863.HKD","LU1699723380.USD","LU1061106388.HKD","LU0320765646.SGD","LU1069347547.HKD","IE00BN8TJ469.HKD","LU0965509101.SGD","BK4533","IE000M9KFDE8.USD","LU1035773651.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2585622140","title":"FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585622140","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585622140?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:52","pubTimestamp":1763747520,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer .The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication.A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALPMY","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1974910355.USD","LU0234572021.USD","LU2468319806.SGD","LU1037948897.HKD","LU1116320901.HKD","LU2324357040.USD","LU1989771016.USD","LU1983299246.USD","LU1571399168.USD","LU2106854487.HKD","SG9999015358.SGD","LU0208291251.USD","LU0265550946.USD","BK4516","IE0009355771.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0965509283.SGD","LU2023250504.SGD","MRK","SG9999014567.USD","LU0320765489.SGD","SG9999001440.SGD","SGXZ57979304.SGD","BK4585","LU1699723380.USD","LU2089984988.USD","LU0238689110.USD","LU0203345920.USD","IE00BBT3K403.USD","LU1941712264.USD","SG9999001176.USD","IE00BJT1NW94.SGD","LU1989772840.SGD","SG9999002224.SGD","LU1066051811.HKD","LU0861579265.USD","LU1035773651.USD","IE0002141913.USD","BK4533","LU1093756168.USD","IE00BLSP4239.USD","LU2461242641.AUD","IE000M9KFDE8.USD","SG9999015341.SGD","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}